SCHEMBL4416241

SCHEMBL4416241

N#Cc1c(Cl)nc(NCc2cccnc2)nc1NCCO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
PDE4D Q08499 1/20 0.50
PKM P14618 1/20 0.47
RAD52 P43351 1/20 0.47
HPGD P15428 4/20 0.47
LMNA P02545 2/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
MAPK10 P53779 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 4/20 0.46
PGK1 P00558 1/20 0.45
MAPT P10636 2/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4414987 0.97 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DPKM
SCHEMBL4420256 0.80 CCNA2 (0.52) HPGDLMNAHTTALDH1A1KDM4E
SCHEMBL7281250 0.79 PDE4A (0.63) PDE4APDE4BPDE4CPDE4DPKM
SCHEMBL4420264 0.78 ALDH1A1 (0.48) PDE4APDE4BPDE4CPDE4DRAD52
SCHEMBL4415014 0.76 TP53 (0.43) PDE4APDE4BPDE4CPDE4DRAD52
SCHEMBL4415000 0.76 ALDH1A1 (0.45) PDE4APDE4BPDE4CPDE4DRAD52
SCHEMBL7327059 0.75 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DHPGD
SCHEMBL4413529 0.74 ALDH1A1 (0.40) PDE4APDE4BPDE4CPDE4DRAD52
SCHEMBL4416386 0.72 CCNA2 (0.47) HPGDLMNAHTTALDH1A1KDM4E
SCHEMBL4413356 0.72 CCNA2 (0.42) HPGDLMNAHTTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397351-B1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS HOFFMANN LA ROCHE (CH) 2009-11-11 EP disclosed
CN-1245391-C Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors HOFFMANN LA ROCHE (CH) 2006-03-15 CN disclosed
CN-1512988-A Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors - 2004-07-14 CN disclosed
EP-1397351-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2004-03-17 EP disclosed
US-6673795-B2 SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. 2004-01-06 US disclosed
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-03-27 US disclosed
WO-2002098864-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives P2RX5, IL5, P2RX2 PDE4A 602/4885PDE4B 889/4885PDE4C 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.